Acute inflammation and psychomotor slowing: Experimental assessment using lipopolysaccharide administration in healthy humans.
Cytokine
Go/no-go
Inflammation
Lipopolysaccharide
Psychomotor slowing
Reaction time
Sickness
Journal
Brain, behavior, & immunity - health
ISSN: 2666-3546
Titre abrégé: Brain Behav Immun Health
Pays: United States
ID NLM: 101759062
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
08
2020
accepted:
18
08
2020
entrez:
30
9
2021
pubmed:
20
8
2020
medline:
20
8
2020
Statut:
epublish
Résumé
Data from clinical and cross-sectional studies suggest that inflammation contributes to psychomotor slowing and attentional deficits found in depressive disorder. However, experimental evidence is still lacking. The aim of this study was to clarify the effect of inflammation on psychomotor slowing using an experimental and acute model of inflammation, in which twenty-two healthy volunteers received an intravenous injection of lipopolysaccharide (LPS, dose: 0.8 ng/kg body weight) and of placebo, in a randomized order following a double-blind within-subject crossover design. A reaction time test and a go/no-go test were conducted 3 h after the LPS/placebo injection and interleukin (IL)-6 and tumor necrosis factor (TNF)-α concentrations were assessed. No effect of experimental inflammation on reaction times or errors for either test was found. However, inflammation was related to worse self-rated performance and lower effort put in the tasks. Exploratory analyses indicated that reaction time fluctuated more over time during acute inflammation. These data indicate that acute inflammation has only modest effects on psychomotor speed and attention in healthy subjects objectively, but alters the subjective evaluation of test performance. Increased variability in reaction time might be the first objective sign of altered psychomotor ability and would merit further investigation.
Identifiants
pubmed: 34589881
doi: 10.1016/j.bbih.2020.100130
pii: S2666-3546(20)30095-8
pmc: PMC8474655
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100130Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Neurosci Biobehav Rev. 2020 Aug;115:15-24
pubmed: 32433924
Mol Psychiatry. 2020 Sep 1;:
pubmed: 32873895
J Affect Disord. 1985 Nov;9(3):213-8
pubmed: 2934454
Neurosci Biobehav Rev. 2010 Jan;34(1):130-43
pubmed: 19666048
Sleep. 2017 Nov 1;40(11):
pubmed: 28958084
Brain Behav Immun. 2015 May;46:17-22
pubmed: 25500218
Transl Psychiatry. 2016 Mar 08;6:e750
pubmed: 26954978
Sleep. 2011 Jan 01;34(1):57-63
pubmed: 21203373
Front Behav Neurosci. 2018 Aug 21;12:183
pubmed: 30186124
Arch Gen Psychiatry. 2012 Oct;69(10):1044-53
pubmed: 23026954
Acta Astronaut. 2011 Dec 1;69(11-12):949-959
pubmed: 22025811
Brain Behav Immun. 2014 Jan;35:1-8
pubmed: 24491305
Brain Behav Immun. 2020 Aug;88:283-293
pubmed: 32485294
Curr Top Behav Neurosci. 2017;31:199-219
pubmed: 27225499
Eur Psychiatry. 2019 Aug;60:63-70
pubmed: 31158611
Am J Psychiatry. 2006 Jan;163(1):73-8
pubmed: 16390892
Front Neuroendocrinol. 2012 Aug;33(3):315-27
pubmed: 23000204
Psychol Bull. 2013 Jan;139(1):213-240
pubmed: 22730921
Brain Behav Immun. 2016 Oct;57:30-37
pubmed: 26790758
Brain Behav Immun. 2008 Aug;22(6):870-80
pubmed: 18258414
Psychol Med. 2020 Apr 21;:1-15
pubmed: 32312344
J Affect Disord. 2003 Nov;77(2):135-41
pubmed: 14607390
Mol Psychiatry. 2017 Oct;22(10):1448-1454
pubmed: 28138158
PLoS One. 2011;6(12):e28330
pubmed: 22164271
Vaccine. 2004 Sep 28;22(29-30):3877-81
pubmed: 15364434
Front Psychiatry. 2019 Jan 09;9:739
pubmed: 30687139
Biol Psychiatry. 2005 Aug 1;58(3):190-6
pubmed: 16084839
Curr Opin Neurobiol. 2013 Oct;23(5):854-63
pubmed: 23523374
Biol Psychiatry. 2008 Jun 1;63(11):1022-9
pubmed: 18242584
Transl Psychiatry. 2017 Dec 11;7(12):1281
pubmed: 29225332
Neuropsychopharmacology. 2017 Mar;42(4):801-810
pubmed: 27620550
Brain Behav Immun. 2016 Aug;56:281-8
pubmed: 27040122
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775